Trial Search Results
Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
To study the safety and feasibility of stereotactic radiation dose escalation following neoadjuvant chemotherapy with concurrent conventionally fractionated radiation, by evaluating the acute and late toxicity of treatment.
Stanford is currently not accepting patients for this trial.
- Drug: Capecitabine (Xeloda)
- Drug: [18-F] Fluorodeoxyglucose (FDG)
- Drug: 5-Fluorouracil (5-FU)
- Drug: Carboplatin
Inclusion Criteria:- Confirmed diagnosis of adenocarcinoma or squamous cell carcinoma of
the esophagus by pathologist.
- Endoscopic ultrasound or CT evidence of tumor penetration through the esophageal wall
or involvement of regional lymph nodes, without evidence of distant metastasis
- No prior chest radiation therapy
- No prior chemotherapy for esophageal cancer
- Age greater than 18 years
- No infections requiring antibiotic treatment
- Able to care for self
- Patients must have acceptable liver, kidney and bone marrow function.
- The effects of the chemotherapy drugs on the developing human fetus are unknown. Women
of child-bearing potential and men must agree to use adequate contraception.
Exclusion Criteria:- Patients receiving any other investigational agents
- Evidence of distant metastases
- Uncontrolled medical illness
- Any malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix.
- Pregnant and breastfeeding women are excluded.
- HIV-positive patients
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study